Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
UTHR Price Action
Last 7 days
6.5%
Last 30 days
1.8%
Last 90 days
51.5%
Trailing 12 Months
19.3%
UTHR RSI Chart
UTHR Valuation
UTHR Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
UTHR Fundamentals
UTHR Revenue
UTHR Earnings
UTHR Profitability
UTHR Investor Care
UTHR Alerts
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 3.0B | 3.1B | 3.1B | 0 |
| 2024 | 2.5B | 2.6B | 2.8B | 2.9B |
| 2023 | 2.0B | 2.1B | 2.2B | 2.3B |
| 2022 | 1.8B | 1.8B | 1.9B | 1.9B |
| 2021 | 1.5B | 1.6B | 1.7B | 1.7B |
| 2020 | 1.4B | 1.4B | 1.4B | 1.5B |
| 2019 | 1.6B | 1.5B | 1.5B | 1.4B |
| 2018 | 1.7B | 1.7B | 1.7B | 1.6B |
| 2017 | 1.6B | 1.6B | 1.7B | 1.7B |
| 2016 | 1.5B | 1.6B | 1.6B | 1.6B |
| 2015 | 1.3B | 1.3B | 1.4B | 1.5B |
| 2014 | 1.2B | 1.2B | 1.2B | 1.3B |
| 2013 | 957.0M | 1.0B | 1.1B | 1.1B |
| 2012 | 784.9M | 826.7M | 867.4M | 916.1M |
| 2011 | 629.5M | 678.5M | 711.7M | 743.2M |
| 2010 | 0 | 0 | 0 | 592.9M |
Get all data in R, Python etc through our Historical Stock Data APIs
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
| CEO | Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. |
|---|---|
| WEBSITE | unither.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 985 |
